1. Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial

2. www. Clinical trial results.org HORIZONS Trial: Study Design Antithrombotic Therapy Randomized 1:1 Antithrombotic Therapy Randomized 1:1 UFH + IIb/IIIa Inhibitor n=1700 n=1700 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients. Presented at TCT 2005 Bivalirudin + Bail-Out IIb/IIIa Inhibitor n=1700 n=1700  Hypothesis 1: Bivalirudin compared to UFH + routine IIb/IIIa will reduce the composite rate of death, reinfarction, TVR, stroke, and major bleeding at 30 days Target Vessel Stenting to DES vs BMS Randomized 3:1

3. www. Clinical trial results.org HORIZONS Trial: Study Design  Hypothesis 2: Use of polymer-based slow-release paclitaxel-eluting TAXUS stent will safely reduce the 1 year rate of ischemia-driven TLR Presented at TCT 2005 Target Vessel Stenting Randomized 3:1 Target Vessel Stenting Randomized 3:1 TAXUS stent n=2250 n=2250 Bare metal Express stent n=750 n=750 Antithrombotic Therapy Randomized 1:1 Antithrombotic Therapy Randomized 1:1 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients. 3400 patients undergoing primary PCI first randomized 1:1 to anti-thrombotic therapy then ~88% (3000) patients randomized 3:1 to target vessel stenting 1, 6, and 12 month follow-up for all patients undergoing primary randomization, angiography at 13 months for 1500 stent randomized patients only, yearly follow-up for 5 years for all patients.